PlateletBio announces $75.5M Series B to extend autoimmune cell therapy

More than two years after PlateletBio landed its first round of fundraising and a contract with the US government, the company announced its Series B round Thursday.

The preclinical stage biotech out of Watertown, MA announced it raised $75.5 million. The round was led by new investors SymBiosis, K2 HealthVentures, and Oxford Finance, and already-existing investors.